Loss of cyclin G1 expression in human uterine leiomyoma cells induces apoptosis

Reproductive Sciences

Volumn 15, Issue 4, 2008, Pages 400-410

  Kwon, Sang Hoon ^a   Park, Joon Cheol ^a   Ramachandran, Sabarish ^a   Cha, Soon Do ^a   Kwon, Kun Young ^a   Park, Jong Ku ^a   Park, Jong Wook ^a   Bae, Insoo ^b   Cho, Chi Heum ^a  

^a Keimyung University   (South Korea)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Apoptosis; Cyclin G1; Cyclin G1 ribbon type antisense oligonucleotides; p53; Uterine leiomyoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE; CASPASE 3; CYCLIN G1; CYCLIN G1 RIAS; EXODEOXYRIBONUCLEASE III; GENOMIC DNA; PROTEIN P21; PROTEIN P27; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NICK END LABELING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UTERUS MYOMA; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DNA FRAGMENTATION; FEMALE; GENE THERAPY; HUMANS; IN SITU NICK-END LABELING; LEIOMYOMA; MYOMETRIUM; OLIGONUCLEOTIDES, ANTISENSE; RATS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 43849093481     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719107314063     Document Type: Article

References (42)

1. Robboy SJ, Bentley RC, Butnor K., Anderson MC Pathology and pathophysiology of uterine smooth-muscle tumors. Environ Health Perspect. 2000 ; 108: 779-784.
2. Stewart EA Uterine fibroids. Lancet. 2001 ; 357: 293-298.
3. ButtramVC, Reiter RC Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981 ; 36: 433-445.
4. Carlson KJ Outcomes of hysterectomy. Clin Obstet Gynecol. 1987 ; 40: 939-946.
5. Ligon AH, Morton CC Genetics of uterine leiomyomata. Genes Chrom Cancer. 2000 ; 28: 235-245.
6. Baek WK, Kim D., Jung N., et al. Increased expression of cyclin G1 in leiomyoma compared with normal myometrium. Am J Obstet Gynecol. 2003 ; 188: 634-639.
7. Horne MC, Goolsby GL, Donaldson KL, et al. Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression. J Biol Chem. 1996 ; 271: 6050-6061.
8. Tamura K., Kanaoka Y., Jinno S., et al. Cyclin G: a new mammalian cyclin with homology to fission yeast Cig1. Oncogene. 1993 ; 8: 2113-2118.
9. Okamoto K., Kamibayashi C., Serrano M., Prives C., Mumby MC, Beach D. p53-dependent association between cyclin G and the B′ subunit of protein phosphatase 2A. Mol Cell Biol. 1996 ; 16: 6593-6602.
10. Jackman MR, Pines JN Cyclins and the G2/M transition. Cancer Surv. 1997 ; 29: 47-73.
11. Fisher RP CDKs and cyclins in transition(s). Curr Opin Genet Dev. 1997 ; 7: 32-38.
12. Bates S., Rowan S., Vousden KH Characterization of human cyclin G1 and G2: DNA damage inducible genes. Oncogene. 1996 ; 13: 1103-1109.
13. Chen DS, Zhu NL, Hung G., et al. Retroviral vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice. Hum Gene Ther. 1997 ; 8: 1667-1674.
14. Skotzko M., Wu LT, Anderson WF, Gordon EM, Hall FL Retroviral vector-mediated gene-transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic-sarcoma cells. Cancer Res. 1995 ; 55: 5493-5498.
15. Jensen MR, Factor VM, Fantozzi A., Helin K., Huh CG, Thorgeirsson SS Reduced hepatic tumor incidence in cyclin G1-deficient mice. Hepatology. 2003 ; 37: 862-870.
16. Bennin DA, Don AS, Brake T., et al. Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B′ subunits in active complexes and induces nuclear aberrations and a G1/S phase cell cycle arrest. J Biol Chem. 2002 ; 277: 27449-27467.
17. Okamoto K., Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 1995 ; 13: 4816-4822.
18. Zauberman A., Lupo A., Oren M. Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites. Oncogene. 1995 ; 10: 2361-2366.
19. Kimura SH, Ikawa M., Ito A., Okabe M., Nojima H. Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene. 2001 ; 20: 3290-3300.
20. Okamoto K., Li H., Jensen MR, et al. Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell. 2002 ; 9: 761-771.
21. Ohtsuka T., Ryu H., Minamishima YA, Ryo A., Lee SW Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene. 2003 ; 22: 1678-1687.
22. Flanagan WM, Wagner RW Potent and selective gene inhibition using antisense oligodeoxynucleotides. Mol Cell Biochem. 1997 ; 172: 213-225.
23. Wagner RW, Matteucci MD, Lewis JG, Gutierrez AJ, Moulds C., Froehler BC Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science. 1993 ; 260: 1510-1513.
24. Moon IJ, Lee Y., Kwak CS, et al. Target site search and effective inhibition of leukaemic cell growth by a covalently closed multiple anti-sense oligonucleotide to c-myb. Biochem J. 2000 ; 346: 295-303.
25. Moon IJ, Choi K., Choi,YK et al. Potent growth inhibition of leukemic cells by novel ribbon-type antisense oligonucleotides to c-myb1. J Biol Chem. 2000 ; 275: 4647-4653.
26. Nam DH, Ramachandran S., Song DK, et al. Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR gamma ligand ciglitizone. Mol Hum Reprod. 2007 ; 13: 829-836.
27. Zaitseva M., Vollenhoven BJ, Rogers PA In vitro culture significantly alters gene expression profiles and reduces differences between myometrial and fibroid smooth muscle cells. Mol Hum Reprod. 2006 ; 12: 187-207.
28. Kwon KY, Jang JH, Choi WI, Ramachandran S., Cho CH, Cagle PT Expression of apoptotic nuclei by ultrastructural terminal deoxyribonucleotidyl transferase mediated dUTP nick end labeling and detection of FasL, caspases and PARP protein molecules in cadmium induced acute alveolar cell injury. Toxicology. 2006 ; 218: 197-204.
29. Verkauf BS Changing trends in treatment of leiomyomata uteri. Curr Opin Obstet Gynecol. 1993 ; 5: 301-310.
30. Corbin A., Beattie CW Inhibition of the pre-ovulatory proestrous gonadotropin surge, ovulation, and pregnancy with a peptide analogue of luteinizing hormone releasing hormone. Endocr Res Commun. 1975 ; 2: 1-23.
31. Rabin D., McNeil LW Pituitary and gonadal desensitization after continuous luteinizing hormone-releasing hormone infusion in normal females. J Clin Endocrinol Metab. 1980 ; 51: 873-876.
32. Johansen JS, Riis BJ, Hassager C., Moen M., Jacobson J., Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab. 1988 ; 67: 701-706.
33. Dawood MY, Lewis V., Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril. 1989 ; 52: 21-26.
34. Friedman AJ, Harrison-Atlas D., Barbieri RL, Benacerraf B., Gleason R., Schiff I. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril. 1989 ; 51: 251-256.
35. Suggitt M., Bibby MC 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res. 2005 ; 11: 971-981.
36. Dean NM, Bennett CF Antisense oligonucleotide-based therapeutics for cancer. Oncogene. 2003 ; 22: 9087-9096.
37. Smith ML, Kontny HU, Bortnick R., Fornace AJ Jr. The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Exp Cell Res. 1997 ; 230: 61-68.
38. Shimizu A., Nishida J., Ueoka Y., et al. Cyclin G contributes to G2/M arrest of cells in response to DNA damage. Biochem Biophys Res Commun. 1998 ; 242: 529-533.
39. Reimer CL, Borras AM, Kurdistani SK, et al. Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells. J Biol Chem. 1999 ; 274: 11022-11029.
40. Zhao L., Samuels T., Winckler S., et al. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. Mol Cancer Res. 2003 ; 1: 195-206.
41. Kimura SH, Ikawa M., Ito A., Okabe M., Nojima H. Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene. 2001 ; 20: 3290-3300.
42. Jensen MR, Factor VM, Fantozzi A., Helin K., Huh CG, Thorgeirsson SS Reduced hepatic tumor incidence in cyclin G1-deficient mice. Hepatology. 2003 ; 37: 862-870.